Form 8-K - Current report:
SEC Accession No. 0001193125-21-146472
Filing Date
2021-05-03
Accepted
2021-05-03 06:06:02
Documents
15
Period of Report
2021-04-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d176034d8k.htm   iXBRL 8-K 32585
2 EX-5.1 d176034dex51.htm EX-5.1 8019
3 EX-10.1 d176034dex101.htm EX-10.1 245898
7 GRAPHIC g176034logo.jpg GRAPHIC 11121
  Complete submission text file 0001193125-21-146472.txt   490011

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ibrx-20210430.xsd EX-101.SCH 3092
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ibrx-20210430_lab.xml EX-101.LAB 17372
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ibrx-20210430_pre.xml EX-101.PRE 10967
8 EXTRACTED XBRL INSTANCE DOCUMENT d176034d8k_htm.xml XML 3234
Mailing Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121
Business Address 3530 JOHN HOPKINS COURT SAN DIEGO CA 92121 (858) 633-0300
ImmunityBio, Inc. (Filer) CIK: 0001326110 (see all company filings)

EIN.: 431979754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37507 | Film No.: 21881143
SIC: 2836 Biological Products, (No Diagnostic Substances)